Showing results (151-160 of 325) with videos related to
Sort By:
Pageof 33
Journal of Medicinal Chemistry|April 30, 2020
Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural StudiesArun K Ghosh, Satish Kovela, Heather L Osswald, et al.Scientific Reports|January 23, 2023
Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variantsKiyoto Tsuchiya, Kenji Maeda, Kouki Matsuda, et al.European Journal of Medicinal Chemistry|May 24, 2023
Synthesis and evaluation of DAG-lactone derivatives with HIV-1 latency reversing activityTakahiro Ishii, Takuya Kobayakawa, Kouki Matsuda, et al.Antimicrobial Agents and Chemotherapy|April 10, 2019
Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant VariantsShin-Ichiro Hattori, Hironori Hayashi, Haydar Bulut, et al.Journal of Medicinal Chemistry|July 9, 2016
Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological EvaluationArun K Ghosh, Heather L Osswald, Kristof Glauninger, et al.Scientific Reports|September 27, 2017
GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitroMasayuki Amano, Pedro Miguel Salcedo-Gómez, Ravikiran S Yedidi, et al.International Journal of Oncology|July 7, 2012
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomideYawara Kawano, Shiho Fujiwara, Naoko Wada, et al.Biochemical and Biophysical Research Communications|March 29, 2017
A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivoNao Nishimura, Shinya Endo, Shikiko Ueno, et al.Journal of Medicinal Chemistry|October 1, 2004
A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosidesMaqbool A Siddiqui, Stephen H Hughes, Paul L Boyer, et al.Molecular Pharmacology|April 20, 2012
Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptaseChristal D Sohl, Rajesh Kasiviswanathan, Jiae Kim, et al.Pageof 33